Sysmex Europe GmbH to Distribute Products for the Analysis of Circulating Tumor Cells in Different Tumor Entities Developed by AdnaGen, a Subsidiary of OncoVista Innovative Therapies, Inc.

NORDERSTEDT, Germany & LANGENHAGEN, Germany--(BUSINESS WIRE)--Sysmex Europe GmbH and AdnaGen AG announced today that they have entered into a non-exclusive European distribution agreement for all current and future AdnaGen proprietary CE-certified diagnostics as well as their research use only (RUO) products. The tests are based on the capture of circulating tumor cells (CTCs) from blood and subsequent detection and profiling of tumor markers.